title: The effect of testosterone aromatization on high-density lipoprotein cholesterol level and postheparin lipolytic activity.
abstract: Stanozolol, an oral 17 alpha-alkylated androgen, increases hepatic triglyceride lipase activity (HTGLA) and decreases high-density lipoprotein cholesterol (HDL-C) levels, whereas intramuscular testosterone has comparatively little effect. In the present study, we tested the hypothesis that aromatization of androgen to estrogen blunts the lipid and lipase effects of exogenous testosterone. Fourteen male weightlifters received testosterone enanthate (200 mg/wk intramuscularly), the aromatase inhibitor testolactone (250 mg four times per day), or both drugs together in a randomized cross-over design. Serum testosterone level increased during all three drug treatments, whereas estradiol level increased only with testosterone alone (+47%, P < .05), demonstrating that testolactone effectively inhibited testosterone aromatization. Testosterone decreased HDL-C(-16%, P < .05), HDL2-C(-23%, NS), and apoprotein (apo) A-I (-12%, P < .05) levels, effects that were consistently but not significantly greater with simultaneous testosterone and testolactone administration (HDL-C, -20%; HDL2-C, -30%; apo A-I, -15%; P < .05 for all). In contrast, both testosterone regimens decreased HDL3-C levels by 13% (P < .05 for both). HTGLA increased 21% during testosterone treatment and 38% during combined testosterone and testolactone treatment (P < .01 for both). Lipoprotein lipase activity (LPLA) increased only during combined testosterone and testolactone treatment (+31%, P < .01), suggesting that estrogen production may counteract the effects of testosterone on LPLA. Testolactone alone had little effect on any lipid, lipoprotein, apoprotein, or lipase concentration.(ABSTRACT TRUNCATED AT 250 WORDS)
authors: Department of Medicine, Miriam Hospital, Providence, RI.
authors: J M
authors: JM
authors: Zmuda
authors: M C
authors: MC
authors: Fahrenbach
authors: B T
authors: BT
authors: Younkin
authors: L L
authors: LL
authors: Bausserman
authors: R B
authors: RB
authors: Terry
authors: D H
authors: DH
authors: Catlin
authors: P D
authors: PD
authors: Thompson
mesh_terms: D000328:Adult; D001141:Aromatase / Q000378:metabolism*; D047072:Aromatase Inhibitors; D008076:Cholesterol, HDL / Q000097:blood*; D004958:Estradiol / Q000097:blood; D005640:Follicle Stimulating Hormone / Q000097:blood; D006493:Heparin / Q000494:pharmacology*; D006801:Humans; D008049:Lipase / Q000097:blood; D008066:Lipolysis; D008071:Lipoprotein Lipase / Q000097:blood; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D013738:Testolactone / Q000494:pharmacology; D013739:Testosterone / Q000097:blood* / Q000494:pharmacology; D014891:Weight Lifting
chemical_list: D047072:Aromatase Inhibitors; D008076:Cholesterol, HDL; D013739:Testosterone; D004958:Estradiol; D013738:Testolactone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D006493:Heparin; D001141:Aromatase; D008049:Lipase; D008071:Lipoprotein Lipase